Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318816 | 1.00 | GAA (0.39) | GAARAB9AKMT2AMEN1KLKB1 | |
| SCHEMBL3690810 | 0.93 | KMT2A (0.45) | KMT2AKLKB1PPARGLDHA | |
| SCHEMBL1309259 | 0.93 | KMT2A (0.45) | KMT2AKLKB1PPARGLDHA | |
| SCHEMBL1310029 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL1310026 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| SCHEMBL1310417 | 0.81 | KMT2A (0.55) | KMT2AGLAPOLBTSHR | |
| SCHEMBL1310421 | 0.81 | KMT2A (0.55) | KMT2AGLAPOLBTSHR | |
| SCHEMBL1308268 | 0.80 | HPGD (0.36) | KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL3683361 | 0.80 | MC4R (0.41) | — | |
| SCHEMBL1309215 | 0.80 | MC4R (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877968-B2 | Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-11-04 | — | — | US | disclosed |
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| EP-2352728-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275657-A1 | MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | GAA 2756/4885RAB9A 1257/4885KMT2A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.